Sugi Predict

Sugi Predict / Compounds / SCHEMBL20583286

SCHEMBL20583286

SCHEMBL20583286

CC(CNNC(=O)c1ccccc1)C(F)(F)F

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.51
▸ NPC1 O15118 2/20 0.51
▸ HDAC3 O15379 7/20 0.46
▸ HDAC1 Q13547 7/20 0.44
▸ HDAC2 Q92769 5/20 0.44
▸ NCOR2 Q9Y618 3/20 0.44
▸ HDAC6 Q9UBN7 3/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ HDAC8 Q9BY41 2/20 0.42
▸ CTDSP1 Q9GZU7 1/20 0.42
▸ PTGS2 P35354 1/20 0.42
▸ MLYCD O95822 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23982620 0.89 RAB9A (0.50) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL5592711 0.82 RAB9A (0.58) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL8910055 0.78 RAB9A (0.54) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL20583509 0.76 SMN1; SMN2 (0.46) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL26110369 0.76 SMN1; SMN2 (0.46) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL27050325 0.75 HDAC3 (0.55) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL20583648 0.73 SMN1; SMN2 (0.44) RAB9ANPC1HDAC3HDAC1HDAC2
SCHEMBL2155964 0.73 CTSL (0.49) RAB9ANPC1ALDH1A1MLYCDHPGD
SCHEMBL2155956 0.73 CTSL (0.49) RAB9ANPC1ALDH1A1MLYCDHPGD
SCHEMBL20583646 0.72 HDAC3 (0.76) RAB9ANPC1HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250090500-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2025-03-20 — — US disclosed
US-12220401-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY, INC. (US) 2025-02-11 — — US disclosed
US-11826351-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY INC. (US) 2023-11-28 — — US disclosed
US-20230372298-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2023-11-23 — — US disclosed
US-11471441-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY INC. (US) 2022-10-18 — — US disclosed
CN-114716381-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-07-08 — — CN disclosed
CN-114634447-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-17 — — CN disclosed
CN-114621146-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-14 — — CN disclosed
CN-114605327-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-10 — — CN disclosed
CN-114591242-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-07 — — CN disclosed
CN-113603645-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2021-11-05 — — CN disclosed
US-20210093611-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2021-04-01 — — US disclosed
EP-3782994-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS Loxo Oncology, Inc. (US) 2021-02-24 — — EP disclosed
US-10918622-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY, INC. (US) 2021-02-16 — — US disclosed
EP-3390395-B1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY INC (US) 2020-09-09 — — EP disclosed
US-20200276162-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2020-09-03 — — US disclosed
US-10464905-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY INC. (US) 2019-11-05 — — US disclosed
US-10342780-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY, INC. (US) 2019-07-09 — — US disclosed
US-20190000806-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2019-01-03 — — US disclosed
US-20180362512-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2018-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12220401-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK RAB9A 2532/4885NPC1 3295/4885HDAC3 1834/4885
US-20250090500-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK RAB9A 2532/4885NPC1 3295/4885HDAC3 1834/4885
US-20180362512-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK RAB9A 2532/4885NPC1 3295/4885HDAC3 1834/4885
US-10918622-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK RAB9A 2532/4885NPC1 3295/4885HDAC3 1834/4885
US-20200276162-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK RAB9A 2532/4885NPC1 3295/4885HDAC3 1834/4885
US-11826351-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK RAB9A 2532/4885NPC1 3295/4885HDAC3 1834/4885
US-11471441-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK RAB9A 2532/4885NPC1 3295/4885HDAC3 1834/4885
US-20230372298-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK RAB9A 2532/4885NPC1 3295/4885HDAC3 1834/4885
US-20210093611-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK RAB9A 2532/4885NPC1 3295/4885HDAC3 1834/4885
US-10464905-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK RAB9A 2532/4885NPC1 3295/4885HDAC3 1834/4885
US-10342780-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK RAB9A 2532/4885NPC1 3295/4885HDAC3 1834/4885
US-20190000806-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK RAB9A 2532/4885NPC1 3295/4885HDAC3 1834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.